1-4 of 4
Thomas Kipps, MD
Close
Sort by
Journal Articles

Wnt5a Induces ROR1 Dependent Tyrosine Phosphorylation of DOCK2, and Enhanced Activation of ERK to Promote Proliferation of CLL Cells

Thomas Kipps, MD, Laura Z. Rassenti, PhD, George F. Widhopf II, PhD, Thomas J. Kipps, MD, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4404.
https://doi.org/10.1182/blood-2018-99-117175
Published: 2018
Journal Articles

Highly Specific Inhibitor for Syk Induces Chronic Lymphocytic Leukemia Cell Apoptosis,

Liguang Chen, MD, PhD, George Chen, B.S., Jessie-Farah Fecteau, Ph.D., Greg Coffey, PhD, Charles Prussak, PhD, Dennis A. Carson, MD, Thomas Kipps, MD
Journal: Blood
Blood (2011) 118 (21): 3875.
https://doi.org/10.1182/blood.V118.21.3875.3875
Published: 2011
Journal Articles

Patterns of Care for Patients with Chronic Lymphocytic Leukemia (CLL): The Connect ® CLL Disease Registry

Jeff Sharman, MD, Christopher R Flowers, MD, Mark Weiss, MD, David Grinblatt, MD, Charles Farber, MD, PhD, Neil Kay, MD, Thomas Kipps, MD, Nicole Lamanna, MD, Chris Pashos, PhD, Ian W Flinn, MD, Mark Kozloff, MD, Susan Lerner, MS, Arlene S Swern, PhD, Kristen A Sullivan, MBA, Thomas K. Street, RPh, Michael Keating, MBBS
Journal: Blood
Blood (2011) 118 (21): 2864.
https://doi.org/10.1182/blood.V118.21.2864.2864
Published: 2011
Journal Articles

IgVH Mutational Status Does Not Affect Complete Remission Rate but Is Associated with Reduced Remission Duration in CLL Patients Treated with Fludarabine, Cyclophosphamide and Rituximab (FCR)-Based Therapy.

Katherine I. Lin, MBBS, BND, Constantine S. Tam, MBBS, Lynne V. Abruzzo, MD, William Wierda, MD, Lynn Barron, Susan O’Brien, MD, Thomas Kipps, MD, Laura Rassenti, PhD, Susan Lerner, MS, Hagop Kantarjian, MD, Michael J. Keating, MD
Journal: Blood
Blood (2007) 110 (11): 753.
https://doi.org/10.1182/blood.V110.11.753.753
Published: 2007